7401-98-1

Basic information

• Product Name: 2,4-dichloro-5-MethylsulfanylpyriMidine
• Synonyms: 2,4-dichloro-5-MethylsulfanylpyriMidine;PyriMidine, 2,4-dichloro-5-(Methylthio)-;2,4-Dichloro-5-(methylthio)pyrimidine;2,4-dichloro-5-mercapto-pyrimidine;1,3-dichloro-4-(methylthio)pyrimidine
• CAS NO: 7401-98-1
• Molecular Formula: C₅H₄Cl₂N₂S
• Molecular Weight: 195.06966
• Mol File: 7401-98-1.mol

Chemical Properties

• Boiling Point: 282.7°Cat760mmHg
• Flash Point: 124.8°C
• Appearance: /
• Density: 1.51g/cm³
• Vapor Pressure: 0.00566mmHg at 25°C
• Refractive Index: 1.611
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -3.19±0.29(Predicted)
• CAS DataBase Reference: 2,4-dichloro-5-MethylsulfanylpyriMidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-dichloro-5-MethylsulfanylpyriMidine(7401-98-1)
• EPA Substance Registry System: 2,4-dichloro-5-MethylsulfanylpyriMidine(7401-98-1)

Safety Data

• Hazardous Substances Data: 7401-98-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,4-dichloro-5-MethylsulfanylpyriMidine is used as a key intermediate compound for the synthesis of bridged heterocyclyl-substituted pyrimidine compounds. These compounds have demonstrated potential in various pharmaceutical applications, particularly in the development of novel therapeutic agents.
The specific application reason for 2,4-dichloro-5-MethylsulfanylpyriMidine in the pharmaceutical industry is its ability to be incorporated into the molecular structure of bridged heterocyclyl-substituted pyrimidine compounds. These compounds have shown promise in the treatment of various diseases and conditions, making them valuable targets for drug development. By using 2,4-dichloro-5-MethylsulfanylpyriMidine as a building block, researchers can design and synthesize new pyrimidine-based drugs with improved efficacy, selectivity, and safety profiles.

InChI:InChI=1/C5H4Cl2N2S/c1-10-3-2-8-5(7)9-4(3)6/h2H,1H3

Upstream product

• 16350-59-7 5-methylsulfanyl-1H-pyrimidine-2,4-dione 
• 16350-59-7 5-mercaptomethyl-uracil 
• 24795-76-4 2,4,6-trichloro-5-methylthio-pyrimidine 

Downstream Products

• 514842-56-9 2,4-dichloro-5-(methylsulfonyl)pyrimidine 
• 1313720-29-4 4-(2-chloro-5-methylthiopyrimidin-4-yl)morpholine 
• 1313720-30-7 4-(5-(methylthio)-4-morpholinopyrimidin-2-yl)benzenamine 
• 1313720-33-0 1-(4-(5-(methylthio)-4-morpholinopyrimidin-2-yl)phenyl)-3-phenylurea 
• 1313720-37-4 phenyl 4-(5-(methylthio)-4-morpholinopyrimidin-2-yl)phenylcarbamate 
• 1313720-52-3 1-(2-aminophenyl)-3-(4-(5-(methylthio)-4-morpholinopyrimidin-2-yl)phenyl)thiourea 
• 1313720-54-5 N-(4-(5-(methylthio)-4-morpholinopyrimidin-2-yl)phenyl)-1H-benzo[d]imidazol-2-amine 
• 1313720-69-2 phenyl 4-(5-(methylsulfinyl)-4-morpholinopyrimidin-2-yl)phenylcarbamate 

Relevant articles and documents

As tyrosine kinase inhibitors of the nitrogen-containing heteroaromatic ring derivatives

The present invention relates to compounds as represented by general formula (I) as tyrosine kinase inhibitors, preparation method thereof, pharmaceutical compositions containing the compounds, and uses thereof for preventing and/or treating instances of B-cell related leukemia, inflammatory diseases and autoimmune diseases, wherein A, ring B, L1, L2, R1, R2, R3, a, b, c, d, e, p and q are as defined in the specification.

MONOCYCLIC PYRIMIDINE/PYRIDINE COMPOUNDS AS INHIBITORS OF P97 COMPLEX

Monocyclic pyrimidine and pyridine compounds having a benzyl amine substituent at the 4 position and a 5:6 bicyclic heteroaryl substituent at the 2 position of the pyrimidine or pyridine ring as well as optional aliphatic, functional and/or aromatic components substituted at other positions of the ring are disclosed. These compounds are inhibitors of the AAA proteasome complex containing p97 and are effective medicinal agents for treatment of diseases associated with p97 bioactivity such as cancer.

Synthesis and structure-activity relationship studies of N -benzyl-2-phenylpyrimidin-4-amine derivatives as potent usp1/uaf1 deubiquitinase inhibitors with anticancer activity against nonsmall cell lung cancer

Deregulation of ubiquitin conjugation or deconjugation has been implicated in the pathogenesis of many human diseases including cancer. The deubiquitinating enzyme USP1 (ubiquitin-specific protease 1), in association with UAF1 (USP1-associated factor 1), is a known regulator of DNA damage response and has been shown as a promising anticancer target. To further evaluate USP1/UAF1 as a therapeutic target, we conducted a quantitative high throughput screen of >400000 compounds and subsequent medicinal chemistry optimization of small molecules that inhibit the deubiquitinating activity of USP1/UAF1. Ultimately, these efforts led to the identification of ML323 (70) and related N-benzyl-2-phenylpyrimidin-4-amine derivatives, which possess nanomolar USP1/UAF1 inhibitory potency. Moreover, we demonstrate a strong correlation between compound IC50 values for USP1/UAF1 inhibition and activity in nonsmall cell lung cancer cells, specifically increased monoubiquitinated PCNA (Ub-PCNA) levels and decreased cell survival. Our results establish the druggability of the USP1/UAF1 deubiquitinase complex and its potential as a molecular target for anticancer therapies.

NOVEL PYRIMIDINE COMPOUNDS AS MTOR AND P13K INHIBITORS

The present invention relates to pyrimidine compounds of formula (I): which are useful in treating mTOR kinase- or PI3K kinase-related diseases.

Pyrimidine derivatives

The present invention relates to trisubstituted pyrimidines of formula (I) 1wherein 0Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses characterised by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.

The anti-H1-histaminic and antimuscarinic effect of 2- and 4-[benzyl-(2-dimethylaminoethyl)amino]pyrimidine compounds

This paper reports the synthesis of 2- and 4- [benzyl-(2-dimethylaminoethyl)amino]pyrimidine compounds and the evaluation of their inhibitory properties against histamine (H1), acetylcholine and barium chloride, on guinea pig isolated ileum. 4-[p.Methoxybenzyl-(2-dimethylaminoethyl)amino]-2-methoxy-pyrimidine (VIII) is shown to possess H1 receptor antagonist activity, with a potency similar to that observed for Tonzylamine. By contrast, a specific, although weak, antimuscarinic effect is displayed by 4-[benzyl-(2-dimethylaminoethyl)amino]-2-methoxy-5-methylthio-pyrimidine (XII).